Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components.Fedosyuk S, Merritt T, Peralta-Alvarez MP, Morris SJ, Lam A, Laroudie N, Kangokar A, Wright D, Warimwe GM, Angell-Manning P, Ritchie AJ, Gilbert SC, Xenopoulos A, Boumlic A, Douglas AD
Vaccine, (2019). 37:6951-6961

Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology.Gilbert SC, Warimwe GM
Vaccine, (2017). 35:4461-4464